BiotechTube

Nivolumab plus Relatlimab FDC

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

—

Conditions

—

Trial Timeline

— → —

NCT ID
NCT05170685

About Nivolumab plus Relatlimab FDC

Nivolumab plus Relatlimab FDC is a pre-clinical stage product being developed by Bristol Myers Squibb for various indications. The current trial status is completed. This product is registered under clinical trial identifier NCT05170685.

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05170685Pre-clinicalCompleted